Published in Drug Week, February 16th, 2007
Until recently, most of the therapeutic research for treating solar lentigines has focused on Caucasian patient populations due to the epidemiological data on the disease. While there have been multiple studies demonstrating that the combination of mequinol 2%, tretinoin 0.01% provides clinically significant improvement in Caucasian patients, little research has been done to evaluate its efficacy in ethnic populations or in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.